MyoKardia_Logo_RGB.png
MyoKardia to Present at 40th Annual Cowen Health Care Conference
February 24, 2020 08:00 ET | MyoKardia, Inc.
BRISBANE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care...
MyoKardia_Logo_RGB.png
MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
February 20, 2020 08:00 ET | MyoKardia, Inc.
BRISBANE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday,...
MyoKardia_Logo_RGB.png
MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 08:00 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38th Annual J.P....
MyoKardia_Logo_RGB.png
MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference
November 27, 2019 08:00 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at...
MyoKardia_Logo_RGB.png
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
November 11, 2019 07:30 ET | MyoKardia, Inc.
Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo...
MyoKardia_Logo_RGB.png
MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten
November 11, 2019 07:30 ET | MyoKardia, Inc.
Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s...
MyoKardia_Logo_RGB.png
MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference
November 06, 2019 16:05 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at...
MyoKardia_Logo_RGB.png
MyoKardia Reports Third Quarter 2019 Financial Results
November 04, 2019 16:44 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the...
MyoKardia_Logo_RGB.png
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
November 04, 2019 08:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...
MyoKardia_Logo_RGB.png
MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
October 28, 2019 08:30 ET | MyoKardia, Inc.
Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study Phase 2 Clinical Trial in Targeted Segment of Genetic DCM to Initiate in 1H 2020 SOUTH SAN...